Quoted from http://www.bloomberg.com/apps/news?pid=20601087&sid=a3cQUIGdgeHM
Biogen Says Eighth Patient Has Infection From Tysabri
By Tom Randall
June 12 (Bloomberg) -- Biogen Idec Inc. said a patient taking its multiple sclerosis drug Tysabri was diagnosed with a life-threatening brain illness, the eighth case reported in the last year.
The patient was confirmed to have progressive multifocal leukoencephalopathy, or PML, on June 10, according to a report on Cambridge, Massachusetts-based Biogen’s Web site. About 56,700 patients have been treated with Tysabri, the company said.
Biogen and marketing partner Elan Corp. pulled Tysabri from the market in 2005 after three patients developed the brain infection, including two who died. The U.S. Food and Drug Administration allowed sales to resume in July 2006 after deciding benefits for slowing MS relapses outweighed the risk. There were no reported infections for about two years after the drug’s reintroduction.